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Introduction {#sec005}
============

Infection, malignant disease, and cardiovascular disease (CVD) are among the major causes of death in renal allograft recipients \[[@pone.0226526.ref001]\]. CVD is strongly related to atherosclerotic lesions, and the risk of cardiovascular events in renal allograft recipients is reportedly 50-times higher than that in healthy individuals \[[@pone.0226526.ref002]\]. Vascular calcification, particularly calcification of the coronary artery, is a strong factor related to such cardiovascular events and cardiovascular death. Furthermore, the progression of atherosclerotic lesions leads to ischemic damage of the renal graft and may cause chronic allograft nephropathy, dyslipidemia, and hypertension \[[@pone.0226526.ref003]\]. Therefore, control of vascular calcification is considered an important issue in both the survival and prognosis of kidney allograft recipients.

Adiponectin (ADPN), which is secreted by fat cells of white and brown adipose tissues, is attracting attention as a factor closely associated with the prevention of coronary artery disease and improvement of insulin sensitivity. ADPN is a physiologically active substance that is secreted by adipose tissue, and acts on local and distant organs. ADPN improves insulin sensitivity, and exhibits anti-diabetic, anti-atherosclerotic, and anti-inflammatory actions, with high-molecular-weight dodecamer and octadecamer ADPN being more closely involved in these actions \[[@pone.0226526.ref004],[@pone.0226526.ref005]\]. There are also C1q/TNF-α related protein (CTRP) family proteins as ADPN paralogs that belong to the C1q/TNF protein superfamily along with ADPN. Among CTRP1 to 15, CTRP9 has the most similar structure to ADPN \[[@pone.0226526.ref006]\]. Specifically, of the 4 dominants that constitute CTRP family proteins, approximately 51% of the amino acids that form the globular C1q domain of CTRP9 are the same as those that constitute the globular domain of ADPN \[[@pone.0226526.ref007]\]. CTRP9 and ADPN form heterotrimers, share adiponectin receptor 1 (AdipoR1), and are physiologically active on vascular endothelial cells and myocardial cells \[[@pone.0226526.ref008]\]. Thus, CTRP9 suppresses TNF-α reactive inflammatory reactions by activating AdipoR1-dependent AMP-activated protein kinase (AMPK), and reduces tissue damage caused by oxidation action associated with glucose uptake. However, the blood level of CTRP9 was reported to be reduced in obese model mice, and its characteristics are similar to those of ADPN. The blood CTRP9 concentration was also reduced in a mouse cardiac ischemia-reperfusion model and myocardial infarction model \[[@pone.0226526.ref009]\]. Thus, in patients with or at a high risk of CVD, CTRP9 secretion may be reduced and its vascular protecting action therefore attenuated.

There has been no report on the relationship of CTRP9 with atherosclerotic lesions in renal allograft recipients. Regarding the relationships of ADPN with lipids, vascular calcification, and cardiovascular complications in patients with chronic kidney graft malfunction, we previously reported that HMW-ADPN is a factor that affects the accumulation of visceral fat, vascular calcification, and the development of CVD \[[@pone.0226526.ref010],[@pone.0226526.ref011]\]. In this study, we noted CTRP9, which is a paralog of ADPN, and evaluated its effects on atherosclerosis and CVD in renal allograft recipients by a retrospective cohort study.

Subjects and methods {#sec006}
====================

Subjects {#sec007}
--------

Our subjects comprised 50 patients (33 males and 17 females) who had undergone renal transplantation at Kanazawa Medical University Hospital and had serum creatinine levels of ≤3 mg/dL, and in whom the transplant had engrafted by the start of the study period in 2008 and engraftment persisted until 2018. We used serum samples taken at fasting condition in this study, and we had a proper diet guidance and food intake was stable at the time of registration in all patients. We prohibited smoking in renal allograft recipients, and excluded a few current smokers even after transplantation.

The following factors were investigated: the age at transplant, sex, donor type (living or deceased renal donor), the time since the transplant, the estimated glomerular filtration rate (eGFR) at the start of the study period, body mass index (BMI), the serum levels of triglyceride (TG), total cholesterol (T chol), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), non-HDL-C (= T chol---HDL-C), and each ADPN fraction (high molecular weight (HMW)-, middle molecular weight (MMW)- and low molecular weight (LMW)-ADPN fractions), CTRP-9, immunosuppressive drug use, anti-diabetic drug (including insulin) use, statin use, anti-hypertensive drug use, and bisphosphonate use.

We evaluated 1) the serum levels of lipid markers, CTRP-9 and ADPN fractions, the renal function of the transplanted organs, and the aortic calcification area index (ACAI); 2) the correlations between serum levels of CTRP-9 and ADPN fractions, and vascular calcification; and 3) the correlations between the serum level of CTRP-9 and HMW-ADPN fraction or lipid markers and allograft function (estimated glomerular filtration rate, eGFR) at the start (2008) and the end (2016) of the study period.

Our study did not include any vulnerable populations, such as prisoners, subjects with reduced mental capacity due to illness or age, or children. In addition, we only used blood samples, radiological scans, and renal biopsy specimens in this study. The study protocol was approved by the ethics committee of Kanazawa Medical University (Kanazawa Medical University Epidemiological Study Review No. I127). All patients provided written informed consent, and the study was conducted according to the principles of the Declaration of Helsinki and Istanbul.

Methods {#sec008}
-------

Serum creatinine levels were analyzed using an enzymatic method, a Hitachi creatinine auto-analyzer (model 7170; Hitachi, Tokyo, Japan), and an enzyme solution (Preauto-SCrE-N; Daiichi Pure Chemicals Co., Tokyo, Japan). The serum levels of T chol, LDL-C, and HDL-C were measured by direct enzymatic assays using an automatic analyzer (Hitachi, Tokyo, Japan). The serum levels of the total, HMW-, MMW-, LMW-ADPN, and CTRP-9 fractions were measured using a sensitive enzyme-linked immunosorbent assay kit (SEKISUI MEDICAL Co., Tokyo, Japan). Renal function was evaluated based on the eGFR (= 194 x SCr^-1.094^ x age^-0.287^ x 0.739 for females, ml/min/1.73 m^2^), which was calculated based on the serum creatinine (SCr) level, as described previously \[[@pone.0226526.ref012]\].

We evaluated calcification of the abdominal aorta using the ACAI. The ACAI was calculated based on assessments of computed tomography scans of the abdominal aortic wall (slice thickness: 5 mm or 10 mm) in the region of interest. Specifically, it was calculated by assessing the percentage of the aortic wall occupied by calcification on each slice and then dividing the sum of the percentage values for all slices by the number of slices ([S1 Fig](#pone.0226526.s001){ref-type="supplementary-material"}). These analyses were conducted using image analysis software (MITANI Co., Ltd., Fukui, Japan).

### Immuno-histopathological examinations {#sec009}

Fresh tissue specimens, which were embedded in OCT compound and frozen in acetone-dry ice mixture, were cut at a thickness of 3 μm on a cryostat. The frozen sections were fixed in a 1:1 mixture of acetone and methanol, and then blocked with 10% goat serum in 0.01 mol/L phosphate-buffered saline. Staining of CTRP9, AdipoR1, and AdipoR2 was performed by indirect immunofluorescence using the primary monoclonal or polyclonal antibodies listed in [S1 Table](#pone.0226526.s003){ref-type="supplementary-material"}. Anti-mouse or rabbit IgG polyclonal goat IgG antibodies conjugated with Alexa Fluor 488 (Thermo Fisher Scientific, A-11029) or Alexa Flour 555 (Thermo Fisher Scientific, A-21429) were used as secondary antibodies, and their signals were visualized using a BX51/DP71 fluorescence microscope/CCD camera (Olympus IMS, Japan).

### Statistical analysis {#sec010}

All continuous variables are presented as the median and interquartile range (IQR). The Mann-Whitney test was used for comparisons between sexes and of the change in the ACAI. The relationships between the serum levels of lipid markers and the serum levels of CTRP9 or each ADPN fraction were evaluated using Spearman's correlation coefficient. The factors influencing the serum CTRP9 level, HMW-ADPN level, and the ACAI were analyzed using multivariate regression analysis. Stat Flex version 6 (Artech Co., Ltd., Osaka, Japan) was used as the statistical analysis software.

The formula for Changes in CTRP9, HMW-ADPN and ACAI is shown below.
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Results {#sec011}
=======

Clinical background {#sec012}
-------------------

The laboratory test results at baseline are shown in [Table 1](#pone.0226526.t001){ref-type="table"}. Comparisons between sexes demonstrated no significant difference in the duration of dialysis or period after transplantation. Moreover, no significant difference was noted in the eGFR at baseline or serum CTRP9 levels in 2008 or in its subsequent changes. The LDL-C level was significantly higher in males (p = 0.001). The HDL-C level was significantly higher (p = 0.001), and the non-HDL-C level was significantly lower (p = 0.001) in females. The serum HMW-ADPN and MMW-ADPN concentrations were higher in females (p = 0.006, p = 0.005). No significant difference was noted in the history of medication.

10.1371/journal.pone.0226526.t001

###### The baseline characteristics.

![](pone.0226526.t001){#pone.0226526.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Valuable                           total               Male                                                   Female
  ---------------------------------- ------------------- ------------------------------------------------------ -----------------------------------------------------
  Donor (living : deceased)          50 (43:7)           33 (29:4)                                              17 (14:3)

  Age at transplant (years)          31.5 (24.0--36.0)   33.0 (23.5--36.3)                                      30.0 (24.3--35.0)

  Duration of dialysis (years)       17.9 (8.3--50.2)    14.7 (8.3--52.6)                                       21.2 (8.2--61.3)

  Time since Tx (months)             284 (217--367)      293 (236--370)                                         231 (201--330)

  BMI (kg/m^2^)                      21.2 (18.8--23.0)   21.3 (18.9--23.2)                                      20.8 (18.8--22.6)

  eGFR in 2008\                      51.3 (42.2--57.1)   52.0 (43.1--62.8)                                      48.3 (39.3--56.3)
  (mL/min/1.73m^2^)                                                                                             

  eGFR in 2016\                      47.6 (39.4--58.0)   52.5 (41.1--59.5)                                      42.8 (38.1--55.4)
  (mL/min/1.73m^2^)                                                                                             

  ΔeGFR\                             -1.8\               -0.25\                                                 -0.2\
  (mL/min/1.73m^2^/year)             (-6.7--2.9)         (-0.58--0.41)                                          (-0.99--0.23)

  Serum Ca (mg/dL)                   9.60 (9.30--9.80)   9.60 (9.40--9.90)                                      9.50 (9.20--9.63)

  Serum phosphorus (mg/dL)           2.95 (2.60--3.20)   2.80 (2.40--3.13)                                      3.10 (2.90--3.40)

  LDL-C (mg/dL)                      103.5\              113.0\                                                 90.0\
                                     (85.0--123.0)       (97.0--132.5)[\*\*](#t001fn004){ref-type="table-fn"}   (76.5--98.3)[\*\*](#t001fn004){ref-type="table-fn"}

  HDL-C (mg/dL)                      61.0\               57.0\                                                  78.0\
                                     (55.0--79.0)        (51.0--67.0)[\*\*](#t001fn004){ref-type="table-fn"}    (66.8--96.5)[\*\*](#t001fn004){ref-type="table-fn"}

  TG (mg/dL)                         126.0\              127.0\                                                 116.0\
                                     (92.0--175.0)       (108.8--186.3)                                         (85.0--169.0)

  non-HDL-C (mg/dL)                  129.6\              144.8\                                                 111.4\
                                     (110.4--153.8)      (121.4--167.7)[\*](#t001fn003){ref-type="table-fn"}    (97.7--131.5) [\*](#t001fn003){ref-type="table-fn"}

  Blood glucose (mg/dL)              95.5\               97.0\                                                  92.0\
                                     (87.0--109.0)       (87.8--122.8)                                          (81.0--99.0)

  Total ADPN in 2008\                7.44\               6.65\                                                  10.20\
  (μg/mL)                            (5.39--10.20)       (4.96--8.43)[\*](#t001fn003){ref-type="table-fn"}      (7.43--11.36)[\*](#t001fn003){ref-type="table-fn"}

  HMW-ADPN (μg/mL)                   2.71\               2.48\                                                  4.52\
                                     (1.68--4.52)        (1.62--3.33)[\*\*](#t001fn004){ref-type="table-fn"}    (3.02--6.79)[\*\*](#t001fn004){ref-type="table-fn"}

  MMW-ADPN (μg/mL)                   1.76\               1.67\                                                  2.26\
                                     (1.18--2.26)        (1.14--1.89)[\*\*](#t001fn004){ref-type="table-fn"}    (1.85--2.83)[\*\*](#t001fn004){ref-type="table-fn"}

  LMW-ADPN (μg/mL)                   2.62 (2.14--3.33)   2.49 (2.15--3.34)                                      2.89 (2.01--3.34)

  CTRP9 in 2008 (ng/mL)              2.05 (2.00--2.13)   2.08 (2.01--2.13)                                      2.03 (2.00--2.07)

  ACAI in 2008                       0.10 (0.00--1.30)   1.72 (0.00--1.55)                                      0.00 (0.00--1.26)

  Therapeutic agents (drug use, %)                                                                              

  Steroids                           50 (100%)           33 (100%)                                              17 (100%)

  Anti-metabolites                   48 (96%)            32 (96%)                                               16 (94%)

  Calcineurin inhibitors             37 (74%)            24 (73%)                                               13 (76%)

  Anti-hypertensive drugs            40 (80%)            29 (88%)                                               11 (65%)

  Anti-diabetic drugs                4 (8%)              3 (9%)                                                 1 (6%)

  Insulin                            2 (4%)              2 (6%)                                                 0 (0%)

  Oral anti-diabetic drugs           2 (4%)              1 (3%)                                                 1 (6%)

  Statins                            35 (70%)            19 (58%)                                               16 (94%)

  Bisphosphonates                    9 (18%)             5 (15%)                                                4 (24%)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: Tx, transplant; eGFR: estimated glomerular filtration rate, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density-lipoprotein cholesterol, TG: triglyceride, ADPN: Adiponectin, HMW: high-molecular-weight, MMW: middle- molecular-weight, LMW: low-molecular-weight, ACAI: aortic calcification area index, CTRP9: C1q/TNF-α related protein-9.

Data are shown as median (IQR) values.

\*:\<0.05

\*\*:\<0.01, male vs. female according to the Mann-Whitney test.

Relationships between the eGFR and serum CTRP9 or ADPN levels in renal graft recipients {#sec013}
---------------------------------------------------------------------------------------

The relationships between renal allograft function and the serum levels of CTRP9 and each ADPN fraction are shown in [S2 Fig](#pone.0226526.s002){ref-type="supplementary-material"}. The CTRP9 and MMW-ADPN level was not significantly correlated with the eGFR (rS = -0.009, p = 0.950, n = 50, rS = -0.218, p = 0.128, n = 50, respectively), whereas the HMW-and LMW-ADPN levels were inversely correlated with the eGFR (rS = -0.319, p = 0.024, n = 50 and rS = -0.372, p = 0.008, n = 50, respectively), as previously reported.

Relationships between the serum CTRP9 level and the serum levels of each lipid marker {#sec014}
-------------------------------------------------------------------------------------

The associations between the serum CTRP9 level and the serum levels of lipid markers at the start of the study period are shown in [S2 Table](#pone.0226526.s004){ref-type="supplementary-material"}. The CTRP9 level was not correlated with the serum levels of HDL-C, LDL-C, TG, or non-HDL-C (rS = 0.020, p = 0.893; rS = 0.239, p = 0.095; rS = 0.041, p = 0.778 and rS = 0.146, p = 0.312, respectively). The CTRP9 level was not correlated with BMI or the change in BMI (rS = 0.138, p = 0.340 and rS = 0.021, p = 0.884, respectively).

Relationships between the changes in CTRP9 and ADPN {#sec015}
---------------------------------------------------

The relationships between the serum CTRP9 and ADPN concentrations at baseline are shown in [Fig 1](#pone.0226526.g001){ref-type="fig"}. In 2008, the serum CTRP concentration was not correlated with the serum HMW-, MMW-, or LMW-ADPN concentration in the same year (\[1A\] rS = -0.226, p = 0.114, \[1B\] rS = 0.129, p = 0.053, and \[1C\] rS = 0.683, p = 0.059). The relationship between the change in the serum CTRP9 concentration and the change in the serum ADPN concentration is shown in [Fig 2](#pone.0226526.g002){ref-type="fig"}. The change in the serum HMW-ADPN concentration was positively correlated with the change in the serum CTRP9 concentration (\[2A rS = 0.437, p = 0.015\]. However, the change in the serum MMW- or LMW-ADPN concentration was not significantly correlated with the change in the serum CTRP9 concentration (\[2B\] sR = 0.129, p = 0.371 and \[2C\] rS = 0.087, p = 0.549). In addition, no significant change of adiponectin fractions during study period over at most 8 years in most cases.

![Relationships between the serum CTRP9 and ADPN levels in renal allograft recipients.\
\[1A\] The serum CTRP concentration at baseline was not significantly correlated with the serum HMW-ADPN concentration in the same year (rS = -0.226, p = 0.114, according to Spearman's rank coefficient). \[1B\] The serum CTRP concentration at baseline was not significantly correlated with the serum MMW-ADPN concentration in the same year (rS = 0.129, p = 0.053, according to Spearman's rank coefficient). \[1C\] The serum CTRP concentration at baseline was not significantly correlated with the LMW-ADPN concentration in the same year (rS = 0.683, p = 0.059, according to Spearman's rank coefficient).](pone.0226526.g001){#pone.0226526.g001}

![Relationships between the change in ADPN and CTRP9 in renal allograft recipients.\
\[2A\] The change in the serum HMW-ADPN concentration during 8 years was positively correlated with the change in the serum CTRP9 concentration during the same period (rS = 0.437, p = 0.015, according to Spearman's rank coefficient). \[2B\] The change in the serum MMW-ADPN concentration was not significantly correlated with the change in the serum CTRP9 concentration during the same period (rS = 0.129, p = 0.371, according to Spearman's rank coefficient). \[2C\] The change in the serum LMW-ADPN concentration was not significantly correlated with the change in the serum CTRP9 concentration (rS = 0.087, p = 0.549, according to Spearman's rank coefficient).](pone.0226526.g002){#pone.0226526.g002}

Relationships between the change in ACAI and CTRP9 {#sec016}
--------------------------------------------------

The relationships of the serum CTRP9 and HMW-ADPN concentrations at baseline with ACAI are shown in [Fig 3](#pone.0226526.g003){ref-type="fig"}. The serum CTRP9 or HMW-ADPN concentration in 2008 was not correlated with ACAI in the same year (\[3A\] rS = 0.154, p = 0.285 and \[3B\] rS = -235, p = 0.100, respectively). The relationships of the change in ACAI with the changes in the serum CTRP9 and ADPN concentrations after 8 years are shown in [Fig 4](#pone.0226526.g004){ref-type="fig"}. The change in the serum CTRP9 concentration was negatively correlated with the change in ACAI (\[4A\] rS = -0.367, p = 0.009\]. The change in the serum HMW-ADPN concentration was also negatively correlated with the change in ACAI (\[4B\] rS = -0.542, p = 0.004).

![Relationships between the serum CTRP9 level and ACAI in renal allograft recipients.\
\[3A\] The serum CTRP concentration at baseline was not significantly correlated with ACAI in the same year (rS = 0.154, p = 0.285, according to Spearman's rank coefficient). \[3B\] The serum HMW-ADPN concentration at baseline was not significantly correlated with ACAI in the same year (rS = -0.235, p = 0.100, according to Spearman's rank coefficient).](pone.0226526.g003){#pone.0226526.g003}

![Relationship between the change in ACAI and CTRP9 in renal allograft recipients.\
\[4A\] The change in the serum CTRP9 concentration during 8 years was negatively correlated with the change in ACAI (rS = -0.367, p = 0.009, according to Spearman's rank coefficient). \[4B\] The change in the serum HMW-ADPN concentration was also negatively correlated with the change in ACAI (rS = -0.542, p = 0.004, according to Spearman's rank coefficient).](pone.0226526.g004){#pone.0226526.g004}

The factors influencing the change in CTRP9 and ACAI in renal transplant subjects {#sec017}
---------------------------------------------------------------------------------

The factors that affected the change in the serum CTRP9 concentration are presented in [Table 2](#pone.0226526.t002){ref-type="table"}. In the multiple regression analysis using the change in the serum CTRP9 concentration as the objective variable, an increase in change in the serum HMW-ADPN concentration was found to be a significant positive factor.

10.1371/journal.pone.0226526.t002

###### Factors influencing the change in CTRP9 in renal transplant subjects.

![](pone.0226526.t002){#pone.0226526.t002g}

  -------------------------------------------------------------------------------
  Objective variable: Change in CTRP9                                     
  ------------------------------------- -------- ------- -------- ------- -------
  (Constant)                            135.3    80.50                    

  Age at\                               -0.648   0.822   -0.116   0.435   0.788
  transplantation (years)                                                 

  Sex (Male = 1, Female = 2)            -9.206   16.95   -0.089   0.590   0.543

  BMI (kg/m^2^)                         -1.207   2.313   0.076    0.605   0.522

  HDL-C (mg/dL)                         -0.122   2.313   -0.048   0.790   0.268

  Duration after\                       -0.133   0.084   -0.216   0.124   1.571
  transplantation (years)                                                 

  Change in\                            97.24    34.51   0.394    0.007   2.818
  HMW-ADPN (μg/mL/year)                                                   
  -------------------------------------------------------------------------------

CTRP9: C1q/TNF-α related protein-9, HMW-ADPN: high-molecular-weight adiponectin, LMW-ADPN: low-molecular-weight adiponectin, ACAI: aortic calcification area index, HDL-C: high-density lipoprotein cholesterol, BMI: body mass index. Explanatory variables: age at transplantation (year), sex, HDL-C (mg/dL), duration after transplantation (year), and change in HMW-ADPN (μg/mL/year). According to multivariate regression analysis.

Regarding factors that affected the change in ACAI, old age at transplantation was an exacerbating factor, whereas an increase in change in the serum CTRP9 concentration was an improving factor ([Table 3](#pone.0226526.t003){ref-type="table"}). Similarly, an increase in change in the serum HMW-ADPN concentration was an improving factor of the change in ACAI ([Table 4](#pone.0226526.t004){ref-type="table"}).

10.1371/journal.pone.0226526.t003

###### Factors influencing ACAI in renal transplant subjects.

![](pone.0226526.t003){#pone.0226526.t003g}

  Objective variable: Change in ACAI　Model 1                                    
  --------------------------------------------- -------- ------- ------- ------- -------
  (Constant)                                    -0.414   0.506                   
  Age at transplantation (years)                0.038    0.113   0.376   0.011   2.639
  Sex (Male = 1, Female = 2)                    -0.043   0.111   0.054   0.740   0.334
  BMI (kg/m^2^)                                 0.015    0.015   0.141   0.329   0.987
  HDL-C (mg/dL)                                 0.000    0.003   0.013   0.943   0.072
  Duration after transplantation (year)         0.000    0.001   0.040   0.773   0.291
  Change of CTRP9 (pg/mL/year)                  -0.002   0.001   0.288   0.041   2.110

CTRP9: C1q/TNF-α related protein-9, ACAI: aortic calcification area index, HDL-C: high-density lipoprotein cholesterol, BMI: body mass index.

Explanatory variables: age at transplantation (year), sex, BMI, HDL-C (mg/dL)

Duration after transplantation (year), and change in CTRP9 (pg/mL/year).

According to multivariate regression analysis.

10.1371/journal.pone.0226526.t004

###### Factors influencing ACAI in renal transplant subjects.

![](pone.0226526.t004){#pone.0226526.t004g}

  ---------------------------------------------------------------------------------------
  Objective variable: Change in ACAI　Model 2                                     
  --------------------------------------------- -------- ------- -------- ------- -------
  (Constant)                                    -0.448   0.476                    

  Age at transplantation (years)                0.013    0.005   0.347    0.017   2.491

  Sex (Male = 1, Female = 2)                    -0.036   0.110   -0.051   0.741   0.332

  BMI (kg/m^2^)                                 0.014    0.014   0.130    0.352   0.941

  HDL-C (mg/dL)                                 0.000    0.003   -0.003   0.985   0.019

  Duration after transplantation (year)         0.000    0.001   0.097    0.463   0.740

  Change in HMW-ADPN\                           -0.610   0.223   -0.362   0.009   2.733
  (μg /mL/year)                                                                   
  ---------------------------------------------------------------------------------------

Explanatory variables: age at transplantation (year), sex, BMI, HDL-C (mg/dL)

Duration after transplantation (year), and change in HMW-ADPN (μg/mL/year)

According to multivariate regression analysis.

Renal expression of CTRP9, AdipoR1, and AdipoR2 {#sec018}
-----------------------------------------------

The findings concerning the expression of CTRP9, and colocalization of AdipoR1 and R2 on vascular endothelial cells in fresh frozen sections of renal graft tissues are presented in [Fig 5](#pone.0226526.g005){ref-type="fig"}. The expression of CTRP9 and AdipoR1 was confirmed in the luminal side of intima, and AdipoR2 expression was confirmed primarily in the media of the arterial wall. Colocalization of CTRP9 and AdipoR1 was demonstrated by merging images, but none was noted about AdipoR2.

![Renal expression of CTRP9 and AdipoR1/R2 in renal allografts.\
Renal biopsy specimens were examined by immunofluorescent multi-staining using anti-CTRP9, anti-AdipoR1, and anti-AdipoR2 antibodies. By merging the images, colocalization of CTRP9 and AdipoR1 was observed in the vascular intima \[5A\], but not in the media of AdipoR2 \[5B\].](pone.0226526.g005){#pone.0226526.g005}

Discussion {#sec019}
==========

This study provided three important results. First, the change in the serum CTRP9 concentration was closely associated with the change in the serum HMW-ADPN concentration in renal allograft recipients. Second, the change in the serum CTRP9 concentration was negatively correlated with the change in ACAI, suggesting that CTRP9 can be a suppressive factor for vascular calcification. Third, the expression of CTRP9 and colocalization of CTRP9 and AdipoR1 were confirmed by fluorescent immunostaining of renal biopsy specimens.

In this study, no significant correlation was observed among the serum CTRP9 and ADPN concentrations at baseline and ACAI. Therefore, their relationship was evaluated using their annual changes. As a result, the change in the serum CTRP9 concentration also exhibited a significant positive correlation with the change in the serum HMW-ADPN concentration in renal allograft recipients. When the multiple regression analysis was performed using the change in the serum CTRP9 concentration as the objective variable, an increase in the serum HMW-ADPN concentration was a significant increasing factor. Concerning this, a relationship between the serum CTRP9 and ADPN concentrations was reported in a previous study using mice. For example, in an obese mouse model, the serum CTRP9 concentration was reduced to a similar degree as the serum ADPN concentration \[[@pone.0226526.ref008]\]. First, CTRP9 and ADPN are both adipocytokines produced by fat cells, and as they are produced by the same tissue, they have close structural similarity. In addition, their expression has been suggested to be suppressed in inflamed tissues. For example, the expression of ADPN is suppressed when insulin resistance-inducing factors, such as TNFα, increase \[[@pone.0226526.ref013]\]. Furthermore, CTRP9 production was also reduced significantly in mice in which inflammation was induced in adipose tissue \[[@pone.0226526.ref014]\]. Therefore, if the same tissue develops chronic inflammation and tissue damage, the production of both CTRP9 and ADPN may be suppressed, possibly explaining the correlation of their changes.

We previously reported that HMW-ADPN is a factor significantly related to the accumulation of visceral fat, vascular calcification, and development of CVD in renal allograft recipients. Moreover, in this study, the serum CTRP9 concentration is also a vascular protective factor in renal allograft recipients. Incidentally, ADPN is a factor that is influenced by several lipid markers, obesity, and the accumulation of visceral fat. For example, it has been demonstrated that the serum ADPN concentration is significantly reduced in obese patients, that the serum HMW-ADPN concentration is negatively correlated with the visceral fat area and eGFR \[[@pone.0226526.ref010]\], and that the serum HMW-ADPN and non-HDL-C concentrations are negatively correlated \[[@pone.0226526.ref011]\]. In this study, however, the serum CTRP9 concentration at baseline was not correlated with any of the lipids examined. Moreover, the visceral fat area is known to be closely correlated with BMI \[[@pone.0226526.ref015]\]. However, no correlation was observed between the serum CTRP9 concentration and eGFR or BMI, or between the serial changes in the serum CTRP9 concentration and BMI in this study. This suggests that CTRP9 acts as an independent factor unaffected by the renal graft function, lipids, or visceral fat, unlike ADPN.

Next, we directed our attention to calcification of the abdominal aorta, which is measured as ACAI, and assessed its changes and relationship with CTRP9. In patients with chronic kidney diseases, vascular calcification is classified into atherosclerotic intimal calcification, which is observed primarily in the aorta and carotid artery, and Möncheberg's medial calcification, which is observed primarily in peripheral middle-sized arteries and arterioles. The two types are mixed in the coronary artery \[[@pone.0226526.ref016]\]. Atherosclerotic intimal calcification and Möncheberg's medial calcification have been demonstrated to be exacerbating factors for all-cause mortality, cardiovascular mortality, and cardiovascular morbidity in the general population \[[@pone.0226526.ref017]\]. In addition, in patients with end-stage renal failure, calcification of the abdominal aorta is a significant prognostic factor for all-cause and cardiovascular deaths \[[@pone.0226526.ref018]\], and its progression was evaluated according to ACAI in this study. As a result, serial changes in ACAI in renal allograft recipients exhibited negative correlations with changes in the serum CTRP9 and HMW-ADPN concentrations. Factors for vascular calcification and atherosclerosis include death of vascular smooth muscle cells and their differentiation into osteogenic/chondrogenic cells, degeneration/degradation of elastin, and remodeling of the vascular wall \[[@pone.0226526.ref019]\]. Degenerated lipids, such as oxidized LDL, generated under oxidative stress, inflammatory cytokines (TNF-α, IFN-γ, IL-1β), and NO are also involved in smooth muscle cell death \[[@pone.0226526.ref020]\]. In Möncheberg's medial calcification, stimuli, including inflammation of the medial smooth muscle layer in the arterial wall, oxidative/mechanical stress, and AGE (advanced glycation end-product), induce vascular wall remodeling and calcification \[[@pone.0226526.ref021]\]. As CTRP9 and ADPN improve insulin sensitivity and have anti-diabetic and anti-inflammatory activity, they may exert suppressive effects on the above mechanism and slow the progression of vascular calcification. Indeed, in patients with coronary artery disease and type 2 diabetes, the serum CTRP9 concentration was found to be correlated with the accumulation of cell adhesion molecules in the vascular wall \[[@pone.0226526.ref022]\]. In addition, a study using human vascular tissues suggested that CTRP9 activates AMPK via AdipoR1 and R2 receptors in common with ADPN in venous smooth muscle cells \[[@pone.0226526.ref023]\]. Moreover, there is a cAMP/PKA-dependent pathway and AMPK-dependent pathway for the development of the function of CTRP9 \[[@pone.0226526.ref024], [@pone.0226526.ref025]\]. Through this pathway, CTRP9 prevents intimal thickening and vascular remodeling in mechanically injured blood vessels \[[@pone.0226526.ref026]\]. Calcification of the abdominal aorta may have been suppressed because of such physiological actions of CTRP9. Furthermore, calcification of the coronary artery has been reported to be observed more frequently in patients with insulin resistance than in the control group, suggesting a similar disease state \[[@pone.0226526.ref027]\]. A decrease in the serum HMW-ADPN concentration is also a risk factor for an increase in cardiovascular events in patients with atherosclerosis, hypertension, and dyslipidemia \[[@pone.0226526.ref028]\]. As increases in CTRP9 and HMW-ADPN were ACAI-improving factors in this study, CTRP9 may have prevented vascular calcification.

In this study, we examined the localization of CTRP9 and its colocalization with AdipoR1 and R2 in the muscular artery wall. CTRP9 was colocalized with AdipoR1 but not with AdipoR2. Regarding the relationship between CTRP9 and AdipoR1, a recent study in mice suggested that CTRP9 suppresses nerve cell apoptosis after cerebral hemorrhage through the AdipoR1-dependent pathway \[[@pone.0226526.ref029]\]. Similarly, the possibility that high glucose-induced vascular endothelial injury is prevented through the AdipoR1-dependent pathway has also been reported \[[@pone.0226526.ref030]\]. In a study using fish, the expression of AdipoR1 mRNA was inhibited, but AdipoR2 was not, after the administration of globular CTRP9 (gCTRP9), suggesting a close relationship between CTRP9 and AdipoR1 \[[@pone.0226526.ref031]\]. In this study, the expression of CTRP9 was consistent with that of AdipoR1 in the intima of human intrarenal muscular arteries; therefore, CTRP9 function was suggested to be mediated by AdipoR1 *in vivo*.

Limitations {#sec020}
-----------

Limitations of this study include 1) the small number of cases, 2) retrospective nature of the study, 3) not using high accuracy inflammatory markers such as sensitive CRP or TNF-α, and 4) limited amount of stained renal biopsy specimens. Given the small number of subjects, is the study at risk for bias due to the population studied (Japanese population) and finding may not be more generalized to other populations. In the future, it will be necessary to evaluate vascular lesions, renal function, inflammation markers, and prognosis by prospective studies, and advances in the histological evaluation of CTRP9 expression in the vascular endothelium, atherosclerosis, and vascular calcification are needed.

Conclusion {#sec021}
==========

In renal allograft recipients, the serum CTRP9 concentration was suggested to change, being positively correlated with the high-molecular-weight ADPN concentration without being affected by the renal function, to prevent the progression of aortic calcification. In addition, AdipoR1 was also suggested to be involved in the function of CTRP9 at the intima of human arteries.

Supporting information {#sec022}
======================

###### The evaluation method of abdominal aortic calcification.

It was calculated by assessing the percentage of the aortic wall occupied by calcification on each slice and then dividing the sum of the percentage values for all slices by the number of slices.

(TIF)

###### 

Click here for additional data file.

###### The relationships between renal allograft function and the serum levels of CTRP9 and each ADPN fraction.

The CTRP9 and MMW-ADPN level was not significantly correlated with the eGFR (rS = -0.009, p = 0.950, n = 50, rS = -0.218, p = 0.128, n = 50, respectively), whereas the HMW-and LMW-ADPN levels were inversely correlated with the eGFR (rS = -0.319, p = 0.024, n = 50 and rS = -0.372, p = 0.008, n = 50, respectively), as previously reported.

(TIF)

###### 

Click here for additional data file.

###### The species, dilution values, and sources of the primary and secondary antibodies.

(TIF)

###### 

Click here for additional data file.

###### Correlations between the serum CTRP9 level and the concentration of each lipid marker.

(TIF)

###### 

Click here for additional data file.

###### CTRP9 dataset.

(XLSX)

###### 

Click here for additional data file.

The authors gratefully acknowledge the help and assistance of their colleagues at the Department of Nephrology.

ACAI

:   aortic calcification area index

Adipo or ADPN

:   adiponectin

CTRP9

:   C1q/TNF-α related protein-9

CVD

:   cardiovascular disease

eGFR

:   estimated glomerular filtration rate

hr

:   hour

sCr

:   serum creatinine
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Dear Dr. Yokoyama,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Sorry for delay of review processes.  Two experts raised several serious concerns to draw your conclusion.  Please revise the manuscript following their comments.

We would appreciate receiving your revised manuscript by Oct 18 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Tatsuo Shimosawa, M.D., Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We noticed you have some minor occurrence(s) of overlapping text with the following previous publication(s), which needs to be addressed:

<https://doi.org/10.1371/journal.pone.0195066>

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the Methods section. Further consideration is dependent on these concerns being addressed.

3\. Please include a separate caption for each figure in your manuscript.

4\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.
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**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This manuscript entitled "Circulating CTRP9 correlates with the prevention of aortic calcification in renal allograft recipients" written by Miyatake et al showed that the change in the serum CTRP9 concentration was positively correlated with the change in the serum HMW-ADPN concentration, and that multiple regression analysis showed that the change in the serum CTRP9 concentration was negatively associated with the change in ACAI. These findings are potentially interesting and useful data to understand the increased development of atherosclerotic lesions in renal allograft recipients. However, their data do not have the important confounding factors, such as high sensitive CRP or TNF-α. In addition, immuno-histological staining of Adipo R1 and R2 is quite poor images.

1\. As the authors mentioned in Discussion, the concentration of CTRP9 and HMW-ADPN is strongly associated with the inflammatory state. Thus, the authors should measure some inflammatory mediators like high sensitive CRP, TNF-α, IL-6.

2\. In Figure 5, the staining of Adipo R1 and R2 looks non-specific. These data do not show the proof of co-localization between CTRP9 and Adipo R1. The authors should exhibit more clear stain. Or, Figure 5 should be removed.

Reviewer \#2: Novelty:

The manuscript is the 1st report on the negative correlation of circulation CTRP9 and aortic calcification in renal transplantation patients.

Major issues:

1\. Renal allograft IS (co-location of CTRP9 and AdipoR1) was not able to lead the conclusion 'CTRP9 and HMW-ADPN were suggested to prevent the progression of aortic calcification through AdipoR1.' Because chronic rejection implicates the allograft vessels directly. To address this concern, animal allogeneic solid organ transplantation model (e.g. heart, kidney or liver) could be set and non-relevant artery (abdominal artery) should be stained for co-location to exclude the direct allorejection background.

2\. What's the relationship of concentration of CTRP9 (and HMW-ADPN) with ACAI at endpoint (2016)?

3\. How were the "concentration changes" calculated? This should be described in "Method" section.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear to Editor,

Thank you very much for your thoughtful comments.

We would like to re--submit the revised manuscript entitled "Circulating CTRP9 correlates with the prevention of aortic calcification in renal allograft recipients''.

We are most grateful to you and the reviewers for the helpful comments on the original version of our manuscript.

We have taken all these comments into account and submit.

According to your reviewer's comments, we improved our manuscripts as below.

The reviewer-1 comments:

This manuscript entitled　"Circulating CTRP9 correlates

with the prevention of aortic calcification in renal allograft recipients" written by Miyatake et al showed that the change in the serum CTRP9 concentration was positively correlated with the change in the serum HMW-ADPN concentration, and that multiple regression analysis showed that the change in the serum CTRP9 concentration was negatively associated with the change in ACAI. These findings are potentially interesting and useful data to understand the increased development of atherosclerotic　 lesions in renal allograft recipients. However, their data do not have the important confounding factors, such as high sensitive CRP or TNF��. In addition, immuno-histological staining of Adipo R1 and R2 is quite poor images.

Comment \#1:

As the authors mentioned in Discussion, the concentration of CTRP9 and HMW-ADPN is strongly associated with the inflammatory state. Thus, the authors should measure some inflammatory mediators like high-sensitive CRP, TNF��, IL-6.

Response:

We think it difficult to measure the mediators such as high-sensitivity CRP, TNF-α, and IL-6, as you pointed out. One reason is that we thought they were not significantly different because we measured them in a stable state, and another reason is the limited amount of sample needed for measurement.

Comment \#2:

In Figure 5, the staining of Adipo R1 and R2 looks non-specific. These data do not show the proof of co-localization between CTRP9 and Adipo R1. The authors should exhibit more clear stain. Or, Figure 5 should be removed.

Response:

We re-stained in another case for Adipo R1 and R2 IS (immunofluorescent staining), to confirm more specific staining. Hence, the conditions of reagents used for staining have been changed. As a result, more specific staining was obtained for CTRP9 and AdipoR1. A clearer colocalization was confirmed. We can send the newly obtained image in a manuscript here.

The reviewer-2 comments:

The manuscript is the 1st report on the negative correlation of circulation CTRP9 and aortic calcification in renal transplantation patients.

Comment \#1:

Renal allograft IS (co-location of CTRP9 and AdipoR1) was not able

to lead the conclusion 'CTRP9 and HMW-ADPN were suggested to prevent the progression of aortic calcification through AdipoR1. Because chronic rejection implicates the allograft vessels directly. To address this concern, animal allogeneic solid organ transplantation model (e.g. heart, kidney or liver) could be set and non-relevant artery (abdominal artery) should be stained for co-location to exclude the direct allorejection background.

Response:

In this study, the proof of CTRP9 and AdipoR1 collocation in renal allograft IS in this study was aimed to show that the CTRP9 expression site coincides with the localization of AdipoR1. As you pointed out, we think that this IS alone cannot prove the process of suppressing vascular calcification. In addition, animal experiments of organ transplantation models, such as your proposal, will be difficult to carry out at our facility.

Comment \#2:

What's the relationship of concentration of CTRP9 (and HMW-ADPN)

with ACAI at endpoint (2016)?

Response:

We couldn't confirm significant correlation CTRP9 and HMW-ADPN concentrations with concurrent ACAI at the 2016 endpoint.

Comment \#3:

How were the "concentration changes" calculated? This should be described in "Method" section.

Response:

We used the calculation method of concentration change is shown below.

Change in CTRP9= {(serum CTRP9 level in 2008)- (serum CTRP9 level in 2016)}/8

Change in HMW ADPN= {(serum HMW-ADPN level in 2008)- (serum HMW-ADPN level in 2016)}/8

Change in ACAI= {(ACAI in 2008)- (ACAIin 2016)}/8

The method for calculating the concentration change is shown in the Method section.

We will continue to make corrections centered on the above points and send the revised manuscript by the due date.

We thank for your advices.

Nobuhiko Miyatake, MD C/O Hitoshi Yokoyama, MD, PhD

Kanazawa Medical University School of Medicine

Department of Nephrology

1-1 Daigaku, Uchinada, Ishikawa 920-0293, JAPAN.

Tel: +81-76-218-8166

FAX: +81-76-286-2786

E-mail: <nobuhiko@kanazawa-med.ac.jp>

###### 

Submitted filename: response to reviewers .docx

###### 

Click here for additional data file.
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Dear Dr. Yokoyama,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The authors could not measure inflammatory markers because they did not plan it and store samples.  It is a limitations of this study.  Authors stated that under stable condition, those markers does not differ.  If so, authors should show scientific proof.

We would appreciate receiving your revised manuscript by Jan 05 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Tatsuo Shimosawa, M.D., Ph.D.

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In my previous comment in the authors' first submission, inflammatory mediators like hs-CRP, TNF-α or IL6 should be measured because the concentration of CTRP9 and HMW-ADPN is strongly associated with the inflammatory state.

However, he authors has not measured at all.

In addition, re-staining of Figure 5 has not successfully shown the colocalization between CTRP9 and AdipoR1.

In total, the authors has not appropriately revised the manuscript at all.

Reviewer \#2: Most of my comments were well addressed, although some of the suggested experimental methods was not able to performed technically.

In the revision, the fonts in line 183-188 are significantly larger than others. Please format.

Furthermore, some of the Figure legends were inserted into the 'Result' section, which confused me.

The manuscript is suitable for publication if the above issues are corrected.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Date: November 26, 2019

Editor office "PLOS ONE"

Dear to Editor,

Thank you very much for your thoughtful comments.

We would like to re--submit the revised manuscript entitled "Circulating CTRP9 correlates with the prevention of aortic calcification in renal allograft recipients''.

We are most grateful to you and the reviewers for the helpful comments on the original version of our manuscript.

We have taken all these comments into account and submit.

According to your reviewer's comments, we improved our manuscripts as below.

Comment \#1:

Thank you very much for your thoughtful comment.

Unfortunately, this study was a retrospective study, then the collected samples were insufficient in some cases. Therefore, it was difficult to measure additionally and to compare with other suggested molecules such as high sensitivity CRP and TNF-α. We added the following sentence in limitation; 3) not using high accurate inflammatory markers such as sensitive CRP or TNF��.

However, the concentration of CTRP9 or HMW-ADPN is also strongly associated with the inflammatory state as we mentioned in Discussion.

We hope our revision certified your comment.

We thank you again for your advice.

Nobuhiko Miyatake, MD C/O Hitoshi Yokoyama, MD, PhD

Kanazawa Medical University School of Medicine

Department of Nephrology

1-1 Daigaku, Uchinada, Ishikawa 920-0293, JAPAN.

Tel: +81-76-218-8166

FAX: +81-76-286-2786

E-mail: <nobuhiko@kanazawa-med.ac.jp>
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